Sana Biotechnology Inc (SANA) - Net Assets
Based on the latest financial reports, Sana Biotechnology Inc (SANA) has net assets worth $119.24 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($373.59 Million) and total liabilities ($254.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Sana Biotechnology Inc (SANA) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $119.24 Million |
| % of Total Assets | 31.92% |
| Annual Growth Rate | N/A |
| 5-Year Change | -77.92% |
| 10-Year Change | N/A |
| Growth Volatility | 10.97 |
Sana Biotechnology Inc - Net Assets Trend (2018–2025)
This chart illustrates how Sana Biotechnology Inc's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Sana Biotechnology Inc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Sana Biotechnology Inc (2018–2025)
The table below shows the annual net assets of Sana Biotechnology Inc from 2018 to 2025. For live valuation and market cap data, see Sana Biotechnology Inc (SANA) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $160.88 Million | -35.78% |
| 2024-12-31 | $250.50 Million | -12.87% |
| 2023-12-31 | $287.51 Million | -42.42% |
| 2022-12-31 | $499.31 Million | -31.46% |
| 2021-12-31 | $728.50 Million | +272.97% |
| 2020-12-31 | $-421.18 Million | -195.48% |
| 2019-12-31 | $-142.54 Million | -980.85% |
| 2018-12-31 | $-13.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sana Biotechnology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 183576900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $27.00K | 0.02% |
| Other Comprehensive Income | $28.00K | 0.02% |
| Other Components | $2.01 Billion | 1249.25% |
| Total Equity | $160.88 Million | 100.00% |
Sana Biotechnology Inc Competitors by Market Cap
The table below lists competitors of Sana Biotechnology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Catalyst Holding Co. Ltd. A
SHG:688267
|
$784.85 Million |
|
Taiwan Chinsan Electronic Industrial Co Ltd
TWO:8042
|
$785.17 Million |
|
Yang Guang Co Ltd
SHE:000608
|
$785.71 Million |
|
Bear Electric Appliance Co Ltd
SHE:002959
|
$785.76 Million |
|
Gujarat Ambuja Exports Limited
NSE:GAEL
|
$784.68 Million |
|
ITE Tech Inc
TW:3014
|
$784.65 Million |
|
Zhejiang Chengbang Landscape
SHG:603316
|
$784.62 Million |
|
Nanjing Kangni Mechanical & Electrical Co Ltd
SHG:603111
|
$784.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sana Biotechnology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 250,504,000 to 160,884,000, a change of -89,620,000 (-35.8%).
- Net loss of 244,166,000 reduced equity.
- Other comprehensive income increased equity by 14,000.
- Other factors increased equity by 154,532,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-244.17 Million | -151.77% |
| Other Comprehensive Income | $14.00K | +0.01% |
| Other Changes | $154.53 Million | +96.05% |
| Total Change | $- | -35.78% |
Book Value vs Market Value Analysis
This analysis compares Sana Biotechnology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.45x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.07 | $2.83 | x |
| 2019-12-31 | $-0.76 | $2.83 | x |
| 2020-12-31 | $-2.25 | $2.83 | x |
| 2021-12-31 | $4.38 | $2.83 | x |
| 2022-12-31 | $2.65 | $2.83 | x |
| 2023-12-31 | $1.48 | $2.83 | x |
| 2024-12-31 | $1.08 | $2.83 | x |
| 2025-12-31 | $0.64 | $2.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sana Biotechnology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -151.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.59x
- Recent ROE (-151.77%) is below the historical average (-57.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.93 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-116.52 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-236.52 Million |
| 2021 | -47.25% | 0.00% | 0.00x | 1.55x | $-417.03 Million |
| 2022 | -53.35% | 0.00% | 0.00x | 1.65x | $-316.32 Million |
| 2023 | -98.52% | 0.00% | 0.00x | 1.97x | $-312.01 Million |
| 2024 | -106.49% | 0.00% | 0.00x | 2.00x | $-291.81 Million |
| 2025 | -151.77% | 0.00% | 0.00x | 2.59x | $-260.25 Million |
Industry Comparison
This section compares Sana Biotechnology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sana Biotechnology Inc (SANA) | $119.24 Million | 0.00% | 2.13x | $784.78 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary… Read more